News coverage about STAAR Surgical (NASDAQ:STAA) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. STAAR Surgical earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 46.3877028879927 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

STAA has been the topic of several recent analyst reports. Canaccord Genuity lifted their price target on shares of STAAR Surgical from $9.00 to $11.00 and gave the company a “hold” rating in a report on Thursday, August 3rd. Zacks Investment Research upgraded shares of STAAR Surgical from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th. Finally, BidaskClub upgraded shares of STAAR Surgical from a “strong sell” rating to a “sell” rating in a report on Friday.

STAAR Surgical (NASDAQ:STAA) traded up 8.29% during mid-day trading on Friday, reaching $11.75. 269,882 shares of the company traded hands. The firm’s market capitalization is $483.03 million. STAAR Surgical has a 12-month low of $7.45 and a 12-month high of $11.90. The company’s 50 day moving average price is $10.48 and its 200 day moving average price is $9.94.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.04. STAAR Surgical had a negative return on equity of 8.69% and a negative net margin of 6.06%. The company had revenue of $21.90 million for the quarter, compared to the consensus estimate of $22.15 million. During the same quarter last year, the company earned ($0.02) earnings per share. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. Equities research analysts predict that STAAR Surgical will post ($0.12) EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at

About STAAR Surgical

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Insider Buying and Selling by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with's FREE daily email newsletter.